Subscribe
shutterstock_547705978_fabio_berti
Fabio Berti / Shutterstock.com
26 October 2020AmericasSarah Morgan

Canada's drug pricing plan prompts backlash

The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Pricing, patents and the PMPRB in Canada
14 December 2020   Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.
Big Pharma
Canada authorises compulsory licences for COVID-19 shortfalls
27 March 2020   Canada is the latest country to adopt emergency measures in order to secure drugs and medical equipment in the fight against COVID-19.
Americas
Pharma industry challenges Canada’s drug pricing plan
9 September 2019   Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Big Pharma
Pricing, patents and the PMPRB in Canada
14 December 2020   Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.
Big Pharma
Canada authorises compulsory licences for COVID-19 shortfalls
27 March 2020   Canada is the latest country to adopt emergency measures in order to secure drugs and medical equipment in the fight against COVID-19.
Americas
Pharma industry challenges Canada’s drug pricing plan
9 September 2019   Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.

More on this story

Big Pharma
Pricing, patents and the PMPRB in Canada
14 December 2020   Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.
Big Pharma
Canada authorises compulsory licences for COVID-19 shortfalls
27 March 2020   Canada is the latest country to adopt emergency measures in order to secure drugs and medical equipment in the fight against COVID-19.
Americas
Pharma industry challenges Canada’s drug pricing plan
9 September 2019   Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.

More features

Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team